Motif Plunges As FDA Demands New Iclaprim Study
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.
You may also be interested in...
Longer follow-up is part of regulatory path forward, the struggling antibiotics firm says after meeting with US FDA to discuss complete response letter.
Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI, Motif needs to raise funds and fast to stay afloat and prepare a meeting package to discuss the next steps for iclaprim with the agency.
The latest drug development news and highlights from our US FDA Performance Tracker.